• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by CAMP4 Therapeutics Corporation

    5/15/26 6:29:53 AM ET
    $CAMP
    Get the next $CAMP alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Camp4 Therapeutics Corp.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)




    13463J101

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    13463J101


    1Names of Reporting Persons

    Balyasny Asset Management L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    2,632,437.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    2,632,437.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,632,437.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.07 %
    12Type of Reporting Person (See Instructions)

    IA, PN


    SCHEDULE 13G

    CUSIP Number(s):
    13463J101


    1Names of Reporting Persons

    BAM GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    2,632,437.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    2,632,437.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,632,437.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.07 %
    12Type of Reporting Person (See Instructions)

    HC, OO


    SCHEDULE 13G

    CUSIP Number(s):
    13463J101


    1Names of Reporting Persons

    Balyasny Asset Management Holdings LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    2,632,437.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    2,632,437.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,632,437.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.07 %
    12Type of Reporting Person (See Instructions)

    HC, PN


    SCHEDULE 13G

    CUSIP Number(s):
    13463J101


    1Names of Reporting Persons

    Dames GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    2,632,437.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    2,632,437.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,632,437.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.07 %
    12Type of Reporting Person (See Instructions)

    HC, OO


    SCHEDULE 13G

    CUSIP Number(s):
    13463J101


    1Names of Reporting Persons

    Dmitry Balyasny
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    2,632,437.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    2,632,437.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,632,437.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.07 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Camp4 Therapeutics Corp.
    (b)Address of issuer's principal executive offices:

    One Kendall Square, Building 1400 West, 3rd Floor, Cambridge, MA 02139
    Item 2. 
    (a)Name of person filing:

    This statement is being filed by (1) Balyasny Asset Management L.P., a Delaware limited partnership ("BAM"), (2) BAM GP LLC, a Delaware limited liability company ("BAM GP"), (3) Balyasny Asset Management Holdings LP, a Delaware limited partnership ("BAM Holdings"), (4) Dames GP LLC, a Delaware limited liability company ("Dames"), and (5) Dmitry Balyasny, a United States citizen (collectively, the "Reporting Persons"). BAM GP is the General Partner of BAM. BAM Holdings is the Sole Member of BAM GP. Dames is the General Partner of BAM Holdings. Dmitry Balyasny is the Managing Member of Dames.
    (b)Address or principal business office or, if none, residence:

    The principal business address of each of BAM, BAM GP, BAM Holdings, Dames, and Mr. Balyasny is located at 444 West Lake Street, 50th Floor, Chicago, IL 60606.
    (c)Citizenship:

    (1) BAM is a Delaware limited partnership, (2) BAM GP is a Delaware limited liability company, (3) BAM Holdings is a Delaware limited partnership, (4) Dames is a Delaware limited liability company, and (5) Mr. Balyasny is a United States citizen.
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP Number(s):

    13463J101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    By virtue of its position as the investment manager of Atlas Diversified Master Fund, Ltd ("ADMF"), the direct holder of 335,392 shares of common stock, par value $0.0001 per share ("Shares"), reported herein, and by virtue of its position as the investment manager of Atlas Private Holdings (Cayman) Ltd. ("APHC"), is the direct holder of the 2,297,045 shares of common stock (including an additional 1,624,523 shares issued upon the exercise of warrants), par value $0.0001 per share, reported herein, BAM may be deemed to exercise voting and investment power over such Shares held by ADMF and APHC and thus may be deemed to beneficially own such Shares. The warrants carry a 4.99% exericse blocker. By virtue of its position as the General Partner of BAM, BAM GP may be deemed to exercise voting and investment power over the Shares held directly by ADMF and APHC and thus may be deemed to beneficially own such Shares. By virtue of its position as the Sole Member of BAM GP, BAM Holdings may be deemed to exercise voting and investment power over the Shares held directly by ADMF and APHC and thus may be deemed to beneficially own such Shares. By virtue of its position as the General Partner of BAM Holdings, Dames may be deemed to exercise voting and investment power over the Shares held directly by ADMF and APHC and thus may be deemed to beneficially own such Shares. By virtue of his position as the Managing Member of Dames, Mr. Balyasny may be deemed to exercise voting and investment power over the Shares held directly by ADMF and APHC and thus may be deemed to beneficially own such Shares.
    (b)Percent of class:

    Each of the Reporting Persons may be deemed to be the beneficial owner of approximately 5.07% of the Shares, based on the 51,919,321 Shares outstanding as of March 4, 2026, as reported in the Issuer's annual report filed on form 10-K with the Securities and Exchange Commission on March 5, 2026. The reported amount consists of 2,632,437 shares and 1,624,523 shares issuable upon the exercise of 1,624,523 warrants subject to the Beneficial Ownership Limitation (as defined herein). The Warrants are subject to a blocker which prevents the holder from exercising the Warrants to the extent that, upon such exercise, the holder would beneficially own in excess of 4.99% of the Shares outstanding as a result of the exercise (the "Beneficial Ownership Limitation").
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Each of the Reporting Persons has the sole power to vote or to direct the vote of 2,632,437 shares.

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    Each of the Reporting Persons has the sole power to vote or to direct the vote of 2,632,437 shares.

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    ADMF and APHC, are both Cayman Islands exempted companies that are investment management clients of BAM, have the right to receive dividends from, or the proceeds from the sale of, the reported securities.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Balyasny Asset Management L.P.
     
    Signature:/s/ Scott Schroeder
    Name/Title:Scott Schroeder / Authorized Signatory
    Date:05/11/2026
     
    BAM GP LLC
     
    Signature:/s/ Scott Schroeder
    Name/Title:Scott Schroeder / Authorized Signatory
    Date:05/11/2026
     
    Balyasny Asset Management Holdings LP
     
    Signature:/s/ Scott Schroeder
    Name/Title:Scott Schroeder / Authorized Signatory
    Date:05/11/2026
     
    Dames GP LLC
     
    Signature:/s/ Scott Schroeder
    Name/Title:Scott Schroeder / Authorized Signatory
    Date:05/11/2026
     
    Dmitry Balyasny
     
    Signature:/s/ Dmitry Balyasny
    Name/Title:Dmitry Balyasny / Self
    Date:05/11/2026
    Get the next $CAMP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CAMP

    DatePrice TargetRatingAnalyst
    6/16/2026$9.00Neutral → Overweight
    Analyst
    6/10/2026$6.50Buy
    Chardan Capital Markets
    4/14/2026$7.00Buy
    Rodman & Renshaw
    10/2/2025$7.00Overweight
    Cantor Fitzgerald
    9/16/2025Overweight → Neutral
    Analyst
    5/27/2025$8.00Outperform
    Wedbush
    11/5/2024Outperform
    William Blair
    11/5/2024$18.00Overweight
    Piper Sandler
    More analyst ratings

    $CAMP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., July 17, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on July 15, 2026 (the "Grant Date"), the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock option to purchase 8,000 shares of the Company’s common stock to a newly hired employee of the Company as an inducement material to such employee’s entry into employment with the Comp

    7/17/26 4:05:00 PM ET
    $CAMP

    X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors

    BOSTON, July 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced the appointment of Kelly Gold to the Company’s Board of Directors effective July 1, 2026, adding strong strategic and financial expertise. Ms. Gold will serve as an independent director and member of the Audit Committee. "We are thrilled to welcome Kelly to our Board of Directors as she brings a distinct combination of financial leadership, capital markets expertise and a scientific background," said Adam Craig, M.D., Ph.D., Executive Chairman of X4 Pharmaceuticals. "As we continue to strengthen our team to align with

    7/1/26 7:00:00 AM ET
    $XFOR
    $CAMP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., June 19, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on June 15, 2026 (the "Grant Date"), the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 39,000 shares of the Company’s common stock to three newly hired employees of the Company, each as an inducement material to such employee’s entry in

    6/19/26 4:05:00 PM ET
    $CAMP

    $CAMP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CAMP4 Therapeutics upgraded by Analyst with a new price target

    Analyst upgraded CAMP4 Therapeutics from Neutral to Overweight and set a new price target of $9.00

    6/16/26 8:10:10 AM ET
    $CAMP

    Chardan Capital Markets initiated coverage on CAMP4 Therapeutics with a new price target

    Chardan Capital Markets initiated coverage of CAMP4 Therapeutics with a rating of Buy and set a new price target of $6.50

    6/10/26 8:27:22 AM ET
    $CAMP

    Rodman & Renshaw initiated coverage on CAMP4 Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of CAMP4 Therapeutics with a rating of Buy and set a new price target of $7.00

    4/14/26 8:19:24 AM ET
    $CAMP

    $CAMP
    SEC Filings

    View All

    CAMP4 Therapeutics Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Camp4 Therapeutics Corp (0001736730) (Filer)

    6/12/26 4:10:37 PM ET
    $CAMP

    SEC Form SCHEDULE 13G filed by CAMP4 Therapeutics Corporation

    SCHEDULE 13G - Camp4 Therapeutics Corp (0001736730) (Subject)

    5/15/26 6:29:53 AM ET
    $CAMP

    CAMP4 Therapeutics Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Camp4 Therapeutics Corp (0001736730) (Filer)

    5/14/26 9:01:44 AM ET
    $CAMP

    $CAMP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Young Richard A

    4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

    6/12/26 4:16:12 PM ET
    $CAMP

    SEC Form 4 filed by Director Schwab Andrew J.

    4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

    6/12/26 4:16:05 PM ET
    $CAMP

    SEC Form 4 filed by Director Williams Douglas E

    4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

    6/12/26 4:16:19 PM ET
    $CAMP

    $CAMP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner 5am Partners Vi, Llc bought $4,499,999 worth of shares (2,941,176 units at $1.53) (SEC Form 4)

    4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

    9/15/25 8:12:20 PM ET
    $CAMP

    Large owner Polaris Management Co. Vii, L.L.C. bought $1,999,999 worth of shares (1,307,189 units at $1.53) (SEC Form 4)

    4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

    9/11/25 4:59:09 PM ET
    $CAMP

    Director Nashat Amir bought $1,999,999 worth of shares (1,307,189 units at $1.53) (SEC Form 4)

    4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

    9/11/25 4:48:30 PM ET
    $CAMP

    $CAMP
    Financials

    Live finance-specific insights

    View All

    CalAmp Reports Third Quarter Fiscal Year 2024 Financial Results

    IRVINE, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company that helps organizations monitor, track and protect their vital assets, today reported financial results for its third quarter of fiscal year 2024 ended November 30, 2023. Third Quarter Fiscal Year 2024 Financial Overview    Revenue was $53.6 million, representing a 13% decline QoQ and a 32% decline YoY driven primarily by softer demand in the TSP market segment.Gross margin was 33%, representing a decline of approximately 340 bps QoQ and 100 bps decline YoY as a result of a shift in product mix and a higher-than-normal reserve for excess and obsolete inventory.S&SS revenue was $34.5

    1/9/24 4:30:00 PM ET
    $CAMP

    CalAmp Announces Date for Fiscal 2024 Third Quarter Earnings Conference Call

    IRVINE, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a leading telematics solution provider that helps organizations improve operational performance, today announced that it will release its fiscal 2024 third quarter financial results after market close on Tuesday, January 9, 2024. In addition, the Company will host a conference call at 5:00 p.m. Eastern (2:00 p.m. Pacific) on January 9, 2024, to discuss its financial results. The call may be accessed via webcast by visiting the Investor Relations section of CalAmp's website at CalAmp IR Web Site. Please go to the website at least 15 minutes early to register, download and install any necessary audio software. A repla

    12/26/23 4:30:00 PM ET
    $CAMP

    CalAmp Announces Completion of Strategic Financing with Lynrock Lake

    IRVINE, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company helping people and organizations improve operational performance with telematics solutions, today announced the closing of a $45 million strategic financing with Lynrock Lake Master Fund LP ("Lynrock") in the form of a term loan maturing in November 2027. Lynrock is an existing holder of a large majority of CalAmp's 2.00% Convertible Senior Notes maturing in August 2025 (the "Notes"). In connection with the execution of the term loan agreement, CalAmp is amending the Notes to add a security interest. "As a long-standing investor in CalAmp, we are pleased to provide the company with add

    12/18/23 4:31:00 PM ET
    $CAMP

    $CAMP
    Leadership Updates

    Live Leadership Updates

    View All

    X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors

    BOSTON, July 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced the appointment of Kelly Gold to the Company’s Board of Directors effective July 1, 2026, adding strong strategic and financial expertise. Ms. Gold will serve as an independent director and member of the Audit Committee. "We are thrilled to welcome Kelly to our Board of Directors as she brings a distinct combination of financial leadership, capital markets expertise and a scientific background," said Adam Craig, M.D., Ph.D., Executive Chairman of X4 Pharmaceuticals. "As we continue to strengthen our team to align with

    7/1/26 7:00:00 AM ET
    $XFOR
    $CAMP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CAMP4 Appoints Michael MacLean to its Board of Directors

    CAMBRIDGE, Mass., March 24, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced the appointment of Michael MacLean to the Company's Board of Directors. "Mike brings an exceptional depth of financial and operational expertise built across decades of leadership at some of the most innovative biotechnology companies, and we are thrilled to welcome him to CAMP4's Board," said Josh Mandel-Brehm, Pr

    3/24/26 7:00:00 AM ET
    $CAMP

    Sequans Appoints Jason W. Cohenour to Board of Directors

    Paris, France--(Newsfile Corp. - June 30, 2025) - Sequans Communications S.A. (NYSE:SQNS), a leading innovator in cellular IoT semiconductor solutions, today announced the appointment of Jason W. Cohenour to its Board of Directors.Mr. Cohenour brings more than 30 years of executive leadership experience across sales, operations, and international mergers and acquisitions. He served as President, CEO, and Director of Sierra Wireless, Inc. (TSX:SW) (NASDAQ:SWIR) from 2005 to 2018, where he led a strategic transformation that created a global leader in the Internet of Things and drove company revenues to nearly USD $800 million. Prior to his CEO role, he held several senior positions at Sierra

    6/30/25 8:00:00 AM ET
    $CAMP
    $LTRX
    $RFIL
    Computer Communications Equipment
    Telecommunications
    Electrical Products
    Technology

    $CAMP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by CAMP4 Therapeutics Corporation

    SC 13G - Camp4 Therapeutics Corp (0001736730) (Subject)

    10/22/24 6:49:57 PM ET
    $CAMP

    SEC Form SC 13D filed by CAMP4 Therapeutics Corporation

    SC 13D - Camp4 Therapeutics Corp (0001736730) (Subject)

    10/22/24 5:50:56 PM ET
    $CAMP

    SEC Form SC 13G filed by CAMP4 Therapeutics Corporation

    SC 13G - Camp4 Therapeutics Corp (0001736730) (Subject)

    10/22/24 4:19:08 PM ET
    $CAMP